Commercial Health Plan and Enrollee Out-of-Pocket Spending on Accelerated Approval Products in 2019
Shelley A Jazowski, Avi U Vaidya, Julie M Donohue, Stacie B Dusetzina, Rachel E Sachs
JAMA Internal Medicine, July 10, 2023
Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019
Sean Dickson, JD, MPH; Nico Gabriel, MA; Walid F. Gellad, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA Health Forum, June 16, 2023
Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
Jing Luo, MD; Robert Feldman, MS; Katherine Callaway Kim, MPH; Scott Rothenberger, PhD; Mary Korytkowski, MD; Inmaculada Hernandez, PharmD, PhD; Walid F. Gellad, MD
JAMA Network Open, June 14, 2023
Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019
Sean R. Dickson, JD, MPH; Nico Gabriel, MA; Walid F. Gellad, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA Network Open, June 14, 2023
National trends in prescription drug expenditures and projections for 2023
Eric M Tichy, PharmD, MBA, BCPS, FCCP, FAST, James M Hoffman, PharmD, MS, Mina Tadrous, PharmD, MS, PhD, Matthew H Rim, PharmD, MS, FASHP, Katie J Suda, PharmD, MS, Sandra Cuellar, PharmD, BCOP, John S Clark, PharmD, MS, BCPS, FASHP, Mary Kate Newell, PhD, MSBA, Glen T Schumock, PharmD, MBA, PhD, FCCP
American Journal of Health-System Pharmacy, April 24, 2023
Pharmaceutical Spending in Fee-for-Service Medicare: Looking Ahead to the Inflation Reduction Act
Walid F. Gellad, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA, October 18, 2022
Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018
Olivier J. Wouters, PhD; Lucas A. Berenbrok, PharmD, MS; Meiqi He, MS; Yihan Li, BS; Inmaculada Hernandez, PharmD, PhD
JAMA Network Open, September 26, 2022
Trends in Out-of-Pocket Cost of Glucagon, 2010-2020
Margaret Zupa, MD; Robert Feldman, MS; Jing Luo, MD
JAMA Network Open, August 30, 2022
Reduction in Medicaid Rebates Paid by Pharmaceutical Manufacturers for Outpatient Injected, Inhaled, Infused, Implanted, or Instilled Drugs: The 5i Loophole
Sean Dickson; Nico Gabriel; Walid Gellad; Inmaculada Hernandez
Journal of Health Politics, Policy, and Law, July 14, 2022
Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits
Rachel E. Sachs; Shelley A. Jazowski; Kyle A. Gavulic; Julie M. Donohue; Stacie B. Dusetzina
Journal of Health Politics, Policy, and Law, July 14, 2022
Doctor's Orders: An Rx to Curb Rising Drug Costs
Alexander Reardon, MD, Utibe Essien, MD, MPH, Jing Luo, MD, MPH, and Quentin R. Youmans, MD, MSc
MedPage Today, June 14, 2022
National trends in prescription drug expenditures and projections for 2022
Eric M Tichy, PharmD, MBA, BCPS, FCCP, FAST, James M Hoffman, PharmD, MS, Katie J Suda, PharmD, MS, Matthew H Rim, PharmD, MS, Mina Tadrous, PharmD, MS, PhD, Sandra Cuellar, PharmD, BCOP, John S Clark, PharmD, MS, BCPS, FASHP, Jennifer Ward, MBA, Glen T Schumock, PharmD, MBA, PhD, FCCP
American Journal of Health-System Pharmacy, April 6, 2022
Comparisons of Insulin Spending and Price Between Canada and the United States
Tyler Schneider, Tara Gomes, Kaleen N. Hayes, Katie J. Suda, Mina Tadrous
Mayo Clinic Proceedings, February 5, 2022
The Costs of Delayed Generic Drug Entry: Evidence from a Controversial Prostate Cancer Drug Patent
David Miller, Benedic Ippolito, Inmaculada Hernandez, Benjamin Davies
Journal of General Internal Medicine, July 13, 2021
Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020
Inmaculada Hernandez, PharmD, PhD; Deanna Rowe, PharmD, MS; Walid F Gellad, MD, MPH; Chester B. Good, MD, MPH
JAMA Network Open, June 2, 2021
A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?
Alvaro San-Juan-Rodriguez, Walid F Gellad, William H Shrank, Chester B Good, Inmaculada Hernandez
Journal of Managed Care and Specialty Pharmacy, May 2021
National trends in prescription drug expenditures and projections for 2021
Eric M Tichy, PharmD, MBA, BCPS, FCCP, FAST, James M Hoffman, PharmD, MS, Katie J Suda, PharmD, MS, Matthew H Rim, PharmD, MS, Mina Tadrous, PharmD, MS, PhD, Sandra Cuellar, PharmD, BCOP, John S Clark, PharmD, MS, BCPS, FASHP, Michelle D Wiest, PharmD, BCPS, FASHP, Linda M Matusiak, MPA, Glen T Schumock, PharmD, MBA, PhD, FCCP
American Journal of Health-System Pharmacy, April 21, 2021
Access to Affordable Insulin and Epinephrine Autoinjectors Through Federally Qualified Health Centers
Gautam Rangavajla, MD; Walid Gellad, MD; Jing Luo, MD
JAMA Health Forum< March 12, 2021
Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors
Alvaro San-Juan-Rodriguez, Vincent M Piro, Chester B Good, Walid F Gellad, Inmaculada Hernandez
Journal of Managed Care and Specialty Pharmacy, January 2021
Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
Jing Luo, MD, MPH; Robert Feldman, MS; Scott D. Rothenberger, PhD; Inmaculada Hernandez, PharmD, PhD; Walid F. Gellad, MD, MPH
JAMA Network Open, October 15, 2020
Effect of Carving in Pharmacy Benefits on Utilization and Costs
Natasha Parekh , MD, MS, Sarah Papa , MS, Alek Drnach , MS, Laura Spiegel , BS, Yan Huang , MS, Chronis Manolis , RPh, Chester B. Good , MD, MPH
Journal of Managed Care and Specialty Pharmacy, October 2020
Estimating Discounts for Top Spending Drugs in Medicare Part D
Inmaculada Hernandez PharmD, PhD, Alvaro San-Juan-Rodriguez PharmD, Chester B. Good MD, MPH & Walid F. Gellad MD, MPH
Journal of General Internal Medicine, September 9, 2020
Drug Shortages and Group Purchasing Organizations-Reply
Julie M Donohue, Inmaculada Hernandez, Tina Batra Hershey
JAMA, August 25, 2020
Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies
Laura K. Ferris, MD, PhD; Walid F. Gellad, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA Dermatology, August 12, 2020
Drug Prices, Rebates, and Discounts—Reply
Inmaculada Hernandez, PharmD, PhD; Walid F. Gellad, MD, MPH
JAMA, July 28, 2020
Cost and Access Implications of Defining CAR-T Therapy as a Drug
Rohan Chalasani, BA; Tina B. Hershey, JD, MPH; Walid F. Gellad, MD, MPH
JAMA Health Forum, July 22, 2020
The US Is Paying Way Too Much for Remdesivir
Rohan Chalasani and Walid Gellad
Wired, July 17, 2020
Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History
Ahmad Masri, MD, MS; Hongya Chen, PharmD; Catherine Wong, MD; Katherine L. Fischer, MSN, RN; Chafic Karam, MD; Walid F. Gellad, MD, MPH; Stephen B. Heitner, MD
JAMA Cardiology, June 17, 2020
Treatments don’t work if we can’t afford them: the global need for open and equitable access to remdesivir
Jing Luo, Gregg Gonsalves, Amy Kapczynski
The BMJ Opinion, June 3, 2020
National trends in prescription drug expenditures and projections for 2020
Eric M Tichy, PharmD, MBA, BCPS, FCCP, FAST, Glen T Schumock, PharmD, MBA, PhD, FCCP, James M Hoffman, PharmD, MS, Katie J Suda, PharmD, MS, Matthew H Rim, PharmD, MS, Mina Tadrous, PharmD, MS, PhD, JoAnn Stubbings, BSPharm, MHCA, Sandra Cuellar, PharmD, BCOP, John S Clark, PharmD, MS, BCPS, FASHP, Michelle D Wiest, PharmD, BCPS, FASHP, Linda M Matusiak, MPA, Robert J Hunkler, MBA, Lee C Vermeulen, BSPharm, MS, FCCP, FFIP
American Journal of Health-System Pharmacy, May 15, 2020
Insulin access and affordability in the USA: anticipating the first interchangeable insulin product
Jing Luo, Aaron S Kesselheim, Ameet Sarpatwari
The Lancet Diabetes and Endocrinology, March 20, 2020
Decreasing Health Care Spending Through Market Competition—A Case for the Rapid Adoption of Adalimumab Biosimilars
Jennifer D. Claytor, MD, MS; Walid Gellad, MD, MPH
JAMA Internal Medicine, March 30, 2020
The Skyrocketing Cost of Rectal Indomethacin
B. Joseph Elmunzer, MD, MSc; Inmaculada Hernandez, PharmD, PhD; Walid F. Gellad, MD, MPH
JAMA Internal Medicine, March 9, 2020
Drug Shortages in the United States: Are Some Prices Too Low?
Inmaculada Hernandez, PharmD, PhD; Tina Batra Hershey, JD, MPH; Julie M. Donohue, PhD
JAMA, March 3, 2020
Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
Inmaculada Hernandez, PharmD, PhD; Alvaro San-Juan-Rodriguez, PharmD; Chester B. Good, MD, MPH; Walid F. Gellad, MD, MPH
JAMA, March 3, 2020
Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer
Inmaculada Hernandez, PharmD, PhD, and Walid F. Gellad, MD, MPH
Journal of Managed Care & Specialty Pharmacy, February 2020
Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin
Jing Luo, Walid F. Gellad
Current Diabetes Reports, January 29, 2020
Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
Alvaro San-Juan-Rodriguez, PharmD; Walid F. Gellad, MD, MPH; Chester B. Good, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA Network Open, December 13, 2019
Adalimumab and the Challenges for Biosimilars
Walid F. Gellad, MD, MPH; Chester B. Good, MD, MPH
JAMA, October 23, 2019
Review of purchases of unapproved medications by the Veterans Health Administration
Ron L Carico, Jr., Pharm.D., M.P.H, Thomas R Emmendorfer, Pharm.D, Sherrie L Aspinall, Pharm.D., M.Sc, Margaret T Mizah, Pharm.D, Chester B Good, M.D., M.P.H
American Journal of Health-System Pharmacy, October 19, 2019
Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending
Ilinca D. Metes, Lingshu Xue, Chung-Chou H. Chang, Haiden A. Huskamp, Walid F. Gellad, Wei-Hsuan Lo-Ciganic, Niteesh K. Choudhry, Seth Richards-Shubik, Hasan Guclu & Julie M. Donohue
BMC Health Services Research, October 16, 2019
Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study
Jing Luo, MD, MPH; Martin Kulldorff, PhD; Ameet Sarpatwari, JD, PhD; Ajinkya Pawar, PhD; Aaron S. Kesselheim, MD, JD, MPH
Annals of Internal Medicine, October 1, 2019
Prescription 2020: Democratic Candidates And Drug Pricing
Rohan Chalasani, Julie M. Donohue, Walid F. Gellad
Health Affairs Blog, August 29, 2019
Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D
Alvaro San-Juan-Rodriguez, PharmD; Chester B. Good, MD, MPH; Rock A. Heyman, MD; Natasha Parekh, MD, MS; William H. Shrank, MD, MSHS; Inmaculada Hernandez, PharmD, PhD
JAMA Neurology, August 26, 2019
Senate Hearings On Drug Prices: Many Questions, Few (Useful) Answers
Inmaculada Hernandez, Walid F. Gellad
Health Affairs Blog, July 24, 2019
Number of Manufacturers and Generic Drug Pricing From 2005 to 2017
Inmaculada Hernandez, PharmD, PhD; Chester B. Good, MD, MPH; Walid F. Gellad, MD, MPH; Natasha Parekh, MD, MS; Meiqi He, MS; and William H. Shrank, MD, MSHS
The American Journal of Managed Care, July 15, 2019
Savings from the EpiPen Authorized Generic: a Retrospective Analysis of Medicaid Data
Inmaculada Hernandez, William H. Shrank, Chester B. Good, Walid F. Gellad
Journal of General Internal Medicine, April 3, 2019
A New Safe Harbor — Turning Drug Rebates into Discounts in Medicare Part D
Walid F. Gellad, M.D., M.P.H., Molly Ennis, M.P.H., and Courtney C. Kuza, Ph.D., M.P.H.
The New England Journal of Medicine, April 3, 2019
Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018
Inmaculada Hernandez, PharmD, PhD; Chester B. Good, MD, MPH; William H. Shrank, MD, MSHS; Walid F. Gellad, MD, MPH
JAMA, March 25, 2019
On The Use Of List Prices In Drug Pricing Research
Inmaculada Hernandez, Walid Gellad
Health Affairs Blog, March 14, 2019
Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors
Alvaro San-Juan-Rodriguez, PharmD; Max V. Prokopovich, BS; William H. Shrank, MD, MSHS; Chester B. Good, MD, MPH; Inmaculada Hernandez, PharmD, PhD
JAMA Internal Medicine, February 18, 2019
Assessment of Spending in Medicare Part D If Medication Prices From the Department of Veterans Affairs Were Used
Brett Venker, PharmD; Kevin B. Stephenson, MD; Walid F. Gellad, MD, MPH
JAMA Internal Medicine, January 14, 2019
The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs
Inmaculada Hernandez, Chester B. Good, David M. Cutler, Walid F. Gellad, Natasha Parekh, and William H. Shrank
Health Affairs, January 7, 2019